A Phase 1 Single and Multiple Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Healthy Participants (Part A) and the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SR604 in Participants With Hemophilia A or Hemophilia B or Factor VII Deficiency (Part B)
Latest Information Update: 15 Oct 2025
At a glance
- Drugs SR 604 (Primary)
- Indications Haemophilia A; Haemophilia B
- Focus Adverse reactions; First in man
- Sponsors Equilibra Bioscience
Most Recent Events
- 09 Oct 2025 The protocol has been amended that in this study only male subjects can participate.
- 13 Mar 2025 Planned number of patients changed from 45 to 36.
- 12 Feb 2025 Status changed from active, no longer recruiting to recruiting.